NRIX Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) is expected to report earnings on October 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.8% since its last earnings release on July 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases.
Sector
Healthcare
Industry
Biotechnology